Insider Transactions in Q3 2025 at Cytokinetics Inc (CYTK)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2025
|
Edward M. Md Kaye Director |
SELL
Open market or private sale
|
Direct |
6,695
-28.82%
|
$368,225
$55.08 P/Share
|
|
Sep 23
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$98,000
$49.28 P/Share
|
|
Sep 23
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.38%
|
$20,000
$10.6 P/Share
|
|
Sep 15
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.32%
|
$245,000
$49.77 P/Share
|
|
Sep 09
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$102,000
$51.29 P/Share
|
|
Sep 09
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.38%
|
$20,000
$10.6 P/Share
|
|
Sep 02
2025
|
Edward M. Md Kaye Director |
SELL
Open market or private sale
|
Direct |
6,756
-22.53%
|
$337,800
$50.0 P/Share
|
|
Sep 02
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.31%
|
$240,000
$48.76 P/Share
|
|
Sep 02
2025
|
Robert Arthur Harrington Director |
SELL
Open market or private sale
|
Direct |
2,150
-9.5%
|
$103,200
$48.67 P/Share
|
|
Aug 19
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$76,000
$38.31 P/Share
|
|
Aug 19
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.38%
|
$20,000
$10.6 P/Share
|
|
Aug 15
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.29%
|
$190,000
$38.42 P/Share
|
|
Aug 05
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$72,000
$36.34 P/Share
|
|
Aug 05
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.38%
|
$20,000
$10.6 P/Share
|
|
Jul 29
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.27%
|
$180,000
$36.45 P/Share
|
|
Jul 22
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$74,000
$37.47 P/Share
|
|
Jul 22
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.38%
|
$20,000
$10.6 P/Share
|
|
Jul 15
2025
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
164
+0.53%
|
$6,232
$38.01 P/Share
|
|
Jul 15
2025
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
559
+0.75%
|
$21,242
$38.01 P/Share
|
|
Jul 15
2025
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
328
+1.43%
|
$12,464
$38.01 P/Share
|
|
Jul 15
2025
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
328
+1.08%
|
$12,464
$38.01 P/Share
|
|
Jul 15
2025
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
164
+0.5%
|
$6,232
$38.01 P/Share
|
|
Jul 14
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.26%
|
$190,000
$38.15 P/Share
|
|
Jul 08
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$66,000
$33.76 P/Share
|
|
Jul 08
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.38%
|
$20,000
$10.6 P/Share
|
|
Jul 01
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.24%
|
$165,000
$33.55 P/Share
|